AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$INO

INOVIO PHARMACEUTICALS, INC.

Price · $INOvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $INO in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $INO in the last 30 days.

Top stories · $INOMore →
MAY 15·openPR.comMed

Investigation Alert: Investors who hold shares of Inovio

An investigation has been launched by the Shareholders Foundation on behalf of long-term investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) regarding potential breaches of fiduciary duties by certain directors. This follows a lawsuit alleging securities law violations after INO's share price plummeted due to delays in FDA submissions for its lead product candidate, INO-3107, and issues with its CELLECTRA device. The investigation concerns whether Inovio directors are liable for false or misleading statements regarding manufacturing, submission timelines, and regulatory prospects.

MAY 14·Stock Titan

INOVIO (NASDAQ: INO) details Q1 loss and INO-3107 accelerated FDA review

INOVIO reported a net loss of $19.7 million for Q1 2026, consistent with the previous year, while significantly reducing operating expenses. The company's lead candidate, INO-3107, is under accelerated FDA review for recurrent respiratory papillomatosis, with a target PDUFA date of October 30, 2026, and INOVIO is preparing for a potential 2026 commercial launch. INOVIO projects its current cash, supplemented by recent equity offering proceeds, will fund operations into Q1 2027, beyond the FDA's decision date for INO-3107.

APR 6·TipRanks

Inovio Pharmaceuticals Announces New Public Equity Offering

Inovio Pharmaceuticals has announced a public offering of 12.5 million shares and accompanying Series A and B warrants at $1.40 per share and warrants. This deal, with an option for underwriters to purchase additional shares, is expected to generate approximately $16 million in net proceeds for the company. The financing aims to support Inovio's DNA medicine programs and bolster its financial standing, especially within the competitive biotech sector.

News on $INO

All news →